Brussels, Belgium, May 17, 2022 (GLOBE NEWSWIRE) --
Description:
Cancer biomarkers are biological molecules that indicate the presence of cancer in a patient. They are produced either by the cancer cells or by noncancer cells in response to cancer.
Use of Cancer Biomarkers Across Different Stages of Cancer Fuels Its Demand
Cancer biomarkers play a critical role in accurately evaluating and managing cancer in different stages. They are used for cancer risk assessment, screening, differential diagnosis, prognosis determination, treatment response prediction, pharmacokinetics/predicting drug doses, and monitoring treatment response. Clinical use of biomarkers for various types of cancer - breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, colon cancer germ cell cancer, and thyroid cancer, amongst others drives its demand.
Growing Prominence of Cancer Biomarkers in Drug Discovery, Development, and Approval Processes
Biomarkers are increasingly being used at every stage of drug discovery and development. The utilization of biomarkers makes the drug discovery, development, and approval processes more efficient. For the successful treatment of complex chronic diseases (such as cancer), to develop precision medicine and targeted therapies, it is critical to monitor the molecular basis of disease initiation and progression before, during, and after the therapeutic intervention. The need to better understand the factors affecting response to drugs has led to an increased demand for additional efficacy, specificity, and safety testing of drugs during new drug development which in turn has bolstered the demand for cancer biomarkers.
Favorable Funding Environment Set to Drive the Growth of Cancer Biomarkers Market
To alleviate the burden of cancer, organizations across the globe are offering funding/grants to discover cancer biomarkers that can treat diseases with unmet needs. For instance,
- Cancer Research UK is offering to fund researchers interested in ‘Biomarker Research’. Through their funding scheme ‘Biomarker Project Awards’, Cancer Research UK is offering 3-year funding of up to £100,000 per year for biomarker assay development, validation, and qualification where there is a clear line of sight to clinical implementation.
- Similarly, the National Institutes of Health (NIH) - Cancer Biomarkers Research Group is offering several funding opportunities for cancer biomarkers.
“Cancer biomarker testing is revolutionizing cancer treatment for several types of tumors. The moment we identify a key biomarker and figure out what is driving tumor growth, we can develop treatment strategies that particularly target the tumor abnormality and eventually improve patient outcomes.” - Director, Leading Cancer Center, United States
Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold in Cancer Biomarkers Market
The cancer biomarkers market is an emerging market marked by the presence of both established and new players. Players operating in the market adopt both organic and inorganic growth strategies such as new product/program launches, partnerships, and acquisitions to garner market share. For instance,
- In March 2022, Vela Diagnostics launched new panels to detect cancer biomarkers.
- In March 2022, SYNLAB partnered with OncoDNA to provide comprehensive biomarker testing for cancer therapy selection in Germany.
Future Outlook of Cancer Biomarkers Market
The global cancer biomarkers market is a promising market that is expected to gain further momentum in the coming years due to technological advancements in genomic and proteomic technologies (gene array technology, improved two-dimensional gel electrophoresis, new mass spectrometric techniques) and bioinformatic tools that showcase the potential to meet the growing demand for new biomarkers that are both sensitive and specific.
To ensure precise evaluation and better clinical cancer management, the demand for prognostic and predictive cancer biomarkers is expected to increase. With the growing development of new treatments, there is a growing requirement for biomarkers that can predict outcomes and direct patients/providers on which treatment options are most likely to be effective for a particular patient with a particular tumor.
Competitive Landscape Analysis: Cancer Biomarkers Market
The Cancer Biomarkers market is marked by the presence of prominent players such as Roche, Thermo Fisher Scientific, QIAGEN, Illumina, Bio-Rad Laboratories, Abbott Laboratories, Sysmex, and others. The foray of players such as R&D Systems, BioVision, Olink, Meso Scale Diagnostics, and others are changing the dynamics of the market and have made the market more competitive.
Explore Detailed Insights on Cancer Biomarkers Market @ https://meditechinsights.com/cancer-biomarkers-market/
About Medi-Tech Insights:
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have successfully completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.
Contact Us:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
